On Dec 13, 2018 AstraZeneca, a global research based biopharmaceutical company, partnered with Guardant Health (US) for the development of CDx tests to commercialize AstraZeneca’s oncology portfolio including Tagrisso and Imfinzi. The CDx test is based on liquid biopsy platform supported by Guardant’s proprietary Digital Sequencing technology.
